Bisantrene hydrochloride is under clinical development by Race Oncology and currently in Phase II for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase II drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Bisantrene hydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Bisantrene hydrochloride overview

Bisantrene hydrochloride (UPI-928) is under development for the treatment of adult and pediatric relapsed and refractory acute myelogenous leukemia, permanent heart damage caused by the chemotherapeutic anthracycline doxorubicin, myelodysplastic syndrome, CMML, breast cancer, ovarian cancer. The drug candidate is a small molecule anthracene derivative. It acts by targeting FTO. It is administered through intravenous route.

Race Oncology overview

Race Oncology discovers and develops novel RNA (ribonucleic acid) directed drugs to treat cancer. The company is investigating Zantrene, a potent small molecule inhibitor of fat mass and obesity associated (FTO) protein for relapsed and refractory acute myeloid leukemia (r/r AML), extramedullary disease (EMD) AML, myelodysplastic syndrome (MDS), and breast cancer. It is also evaluating Zantrene against solid tumors, melanoma, clear cell renal cell carcinoma, and lung cancer. The company’s product candidate acts as an anthracycline-like chemotherapeutic causing less cardiotoxicity (heart damage) in cancer patients. Race Oncology is headquartered in Sydney, New South Wales, Australia.

For a complete picture of Bisantrene hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.